Skip to main content
SpringerLink
Log in

Efficacy and Safety of Selective Serotonin Reuptake Inhibitors in the Treatment of Depression in Children and Adolescents

Practitioner Review

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background: Given the widespread reports involving the use of selective serotonin reuptake inhibitors (SSRIs) in children, the present paper reviews and discusses published double-blind, placebo-controlled studies assessing the safety and efficacy of SSRIs in children and adolescents with major depressive disorder.

Methods: Published and unpublished double-blind, placebo-controlled studies of SSRIs in children and adolescents with depression during the years 1990-2004 were reviewed. A MEDLINE search was performed using the words ‘depression’, ‘randomised controlled trial’, ‘SSRIs’, ‘children’ and ‘adolescents’. The GlaxoSmithKline website was also searched for relevant studies on paroxetine. Outcome measures were the Clinical Global Impressions scale, the Children’s Depression Rating Scale-Revised, the Hamilton Rating Scale for Depression, the depression subscales of the Kiddie Schedule for Affective Disorders and Schizophrenia for Adolescents-Lifetime version, and the Montgomery and Asberg Depression Rating Scale. Adverse effects and withdrawal rates are reported.

Results: There were seven randomised, placebo-controlled trials involving 1619 children and adolescents aged 6–18 years in total. The SSRIs fluoxetine, paroxetine, sertraline and citalopram were reported to exhibit safety and efficacy for treatment of depression in children and adolescents. Reanalysis of published and unpublished studies by the US FDA and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) raised alerts regarding higher suicidal ideation rates from SSRIs in this population. Present guidelines are discussed.

Conclusions: SSRIs remain a first-line pharmacological treatment for depression in children and adolescents for whom psychotherapy has failed or is unavailable. Suicidal ideation and behaviours merit close monitoring. More studies are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. American Academy of Child and Adolescent Psychiatry. Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 1998; 37: 1234–8

    Article  Google Scholar 

  2. Kessler RC, Walters EE. Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the national comorbidity survey. Depress Anxiety 1998; 7: 3–14

    Article  PubMed  CAS  Google Scholar 

  3. Rao U, Ryan ND, Birmaher B, et al. Unipolar depression in adolescents: clinical outcome in adulthood. J Am Acad Child Adolesc Psychiatry 1995; 34: 566–78

    Article  PubMed  CAS  Google Scholar 

  4. Weissman MM, Wolk S, Goldstein RB, et al. Depressed adolescents grown up. JAMA 1999; 281: 1707–13

    Article  PubMed  CAS  Google Scholar 

  5. Dulcan MK, Martini DR. Child and adolescent psychiatry. Washington, DC: American Psychiatric Press Inc., 1999

  6. Anderson RN. Deaths: leading causes for 2000. Natl Vital Stat Rep 2002; 50: 1–85

    PubMed  Google Scholar 

  7. Kandel DB, Davies M. Adult sequelae of adolescent depressive symptoms. Arch Gen Psychiatry 1986; 43: 255–62

    Article  PubMed  CAS  Google Scholar 

  8. Sood AB, Weller E, Weller R. SSRIs in children and adolescents. Curr Psychiatry 2004; 3: 83–9

    Google Scholar 

  9. Hazell P, O’Connell D, Heathcote D, et al. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ 1995; 310: 897–901

    Article  PubMed  CAS  Google Scholar 

  10. Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol 2000 Spring; 10(1): 27–34

    Article  PubMed  CAS  Google Scholar 

  11. Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding. Arch Intern Med 2003; 163: 59–64

    Article  PubMed  CAS  Google Scholar 

  12. GlaxoSmithKline Website. Study #377 [online]. Available from URL: http://www.gsk.com/media/paroxetine.htm [Accessed 2006 Apr 11]

  13. Poznanski E, Mokros H. Children’s Depression Rating Scale-Revised (CDRS-R). Los Angeles, CA: WPS; 1995

    Google Scholar 

  14. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare, 1976

    Google Scholar 

  15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62

    Article  PubMed  CAS  Google Scholar 

  16. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978; 35: 837–44

    Article  PubMed  CAS  Google Scholar 

  17. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9

    Article  PubMed  CAS  Google Scholar 

  18. March J, Silva S, Petrycki S, et al. Treatment for Adolescents with Depression Study (TADS): fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. JAMA 2004; 292: 807–20

    Article  PubMed  CAS  Google Scholar 

  19. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 1205–15

    Article  PubMed  Google Scholar 

  20. Keller MB, Neal RD, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 762–72

    Article  PubMed  CAS  Google Scholar 

  21. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031–7

    Article  PubMed  CAS  Google Scholar 

  22. Emslie GJ, Wagner KD, Kutcher SP, et al. Paroxetine treatment in children and adolescents with major depressive disorder. Presented at the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington DC, 2004.

  23. Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder. JAMA 2003; 290: 1022–41

    Article  Google Scholar 

  24. Wagner KD, Robb AS, Findling RL, et al. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 2004; 161: 1079–83

    Article  PubMed  Google Scholar 

  25. Simeon JG, Dinicola VF, Ferguson HB, et al. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 791–5

    Article  PubMed  CAS  Google Scholar 

  26. MHRA Website: Committee on Safety of Medicines [online]. Available from URL: http://medicines.mhra.gov.uk/aboutagency/regframework/csm/cshome. [Accessed 2006 Apr 12)]

  27. Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychology and Psychiatry 2005; 46(7): 735–54

    Article  Google Scholar 

  28. Food and Drug Administration Website. Worsening depression and suicidality in patients being treated with antidepressants medications [online]. Available from URL: http://www.fda.gov/cder/drug/antidepressants. [Accessed 2006} Apr 11].

  29. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341–5

    Article  PubMed  CAS  Google Scholar 

  30. Olfson M, Shafer D, Marcus SD, et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60: 978–82

    PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to thank Carla Meister for technical support. This study received no external funding, and the authors have no potential conflicts of interest that are directly relevant to the contents of this study.

Author information

Authors and Affiliations

  1. University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, Kansas, 66160, USA

    Susan C. Sharp &  Jessica A. Hellings

Authors
  1. Susan C. Sharp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jessica A. Hellings
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jessica A. Hellings.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharp, S.C., Hellings, J.A. Efficacy and Safety of Selective Serotonin Reuptake Inhibitors in the Treatment of Depression in Children and Adolescents. Clin. Drug Investig. 26, 247–255 (2006). https://doi.org/10.2165/00044011-200626050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200626050-00002

Keywords

Search

Navigation